Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;31(39):6429-6435.
doi: 10.2174/0929867331666230809100021.

Roles of PCSK9 in the Pathogenesis of Periodontal Disease

Motahareh Khosrojerdi  1 , Željko Reiner  1 , Negin Vatanparast  2 , Tannaz Jamialahmadi  3 , Prashant Kesharwani  4   5 , Amirhossein Sahebkar  3   6
Affiliations
Review

Roles of PCSK9 in the Pathogenesis of Periodontal Disease

Motahareh Khosrojerdi et al. Curr Med Chem. 2024.

Abstract

Proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors are FDA-approved drugs recommended for high-risk patients with LDL-cholesterol (LDL-c) levels ≥ 70 mg/dl. Several studies have also investigated the relationship between PCSK9 and periodontitis. Specifically, studies have investigated the association between periodontitis and periodontal PCSK9 levels in humans, and periodontium status in PCSK9-knockout versus wild-type mice. While a positive association between periodontitis and periodontal PCSK9 levels has been noted, the findings on the comparison of periodontium status between PCSK9-knockout and wild-type mice have been inconsistent. Different methodologies among these studies may explain this discrepancy. Future experimental studies on the impact of pharmacological PCSK9 inhibition on periodontal status as well as observational studies comparing periodontium status between patients receiving PCSK9 inhibitors and those receiving other lipid-lowering drugs will shed light on the role of PCSK9 in periodontal health and disease.

Keywords: PCSK9; inflammation; oral health; periodontal; periodontitis; periodontium..

PubMed Disclaimer

References

    1. Rosenson R.S.; Hegele R.A.; Fazio S.; Cannon C.P.; The evolving future of PCSK9 inhibitors. J Am Coll Cardiol 2018,72(3),314-329 - DOI - PubMed
    1. Jia X.; Al Rifai M.; Saeed A.; Ballantyne C.M.; Virani S.S.; PCSK9 inhibitors in the management of cardiovascular risk: A practical guidance. Vasc Health Risk Manag 2022,18,555-566 - DOI - PubMed
    1. Sahebkar A.; Watts G.F.; New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther 2013,35(8),1082-1098 - DOI - PubMed
    1. Zijlstra L.E.; Mooijaart S.P.; Jukema J.W.; PCSK9 inhibition in high-risk patients. Aging 2019,11(23),10791-10792 - DOI - PubMed
    1. Cesaro A.; Bianconi V.; Gragnano F.; Moscarella E.; Fimiani F.; Monda E.; Scudiero O.; Limongelli G.; Pirro M.; Calabrò P.; Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition. Biofactors 2020,46(3),367-380 - DOI - PubMed

LinkOut - more resources